Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Update

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 131,400 shares, an increase of 66.5% from the November 30th total of 78,900 shares. Based on an average daily trading volume, of 3,090,000 shares, the short-interest ratio is currently 0.0 days. Currently, 4.8% of the shares of the company are short sold.

Institutional Trading of Theriva Biologics

An institutional investor recently bought a new position in Theriva Biologics stock. Anson Funds Management LP purchased a new stake in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) during the third quarter, according to its most recent filing with the SEC. The fund purchased 139,046 shares of the company’s stock, valued at approximately $192,000. Anson Funds Management LP owned about 6.13% of Theriva Biologics as of its most recent filing with the SEC. Institutional investors own 6.17% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Maxim Group lowered their target price on Theriva Biologics from $25.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.

Theriva Biologics Trading Down 7.0 %

Theriva Biologics stock traded down $0.11 during midday trading on Friday, hitting $1.47. The stock had a trading volume of 295,151 shares, compared to its average volume of 969,692. Theriva Biologics has a 52-week low of $1.14 and a 52-week high of $17.11. The firm has a market capitalization of $4.09 million, a price-to-earnings ratio of -0.04 and a beta of 1.33.

Theriva Biologics (NYSEAMERICAN:TOVX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($6.81) earnings per share for the quarter, missing analysts’ consensus estimates of ($6.25) by ($0.56).

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.